Navigation Links
Cardiogenesis Reports Second Quarter 2009 Results
Date:8/13/2009

IRVINE, Calif., Aug. 13 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP), a leading developer of surgical products used in the treatment of patients suffering from severe angina, today reported financial results for its second quarter ended June 30, 2009.

Net revenues in the second quarter of 2009 totaled $2,236,000, a 46% decrease from the prior year second quarter net revenues of $4,119,000. The decrease in net revenue for the three months ended June 30, 2009 results primarily from the absence of laser sales in the current year quarter.

Net revenues in the first six months of 2009 totaled $5,088,000, a decrease of approximately 28% from net revenues of $7,101,000 in the first six months of 2008. The year to date decrease as compared with the prior year period is primarily attributable to a $1,459,000, or 66%, decrease in laser sales and a $635,000, or 15%, decrease in disposable handpiece revenue.

Paul McCormick, Executive Chairman, noted, "Although we face a very challenging capital equipment environment, we are pleased to note that total domestic handpiece revenue was up sequentially, which we believe to be an early response to our marketing strategy to focus on building the revenue stream from its consumables by re-engaging the cardiology community. We plan on providing more detail on our growth strategies on today's conference call."

The Company reported a second quarter 2009 operating loss of $562,000 as compared with an operating income of $582,000 in the prior year quarter. The net loss for the quarter was $590,000 or $0.01 per basic and diluted share, as compared with net income of $602,000, or $0.01 per basic and diluted share in the 2008 second quarter.

For the first six months of 2009, Cardiogenesis reported an operating loss of $859,000 as compared with operating income of $545,000 for the same period in the prior year. The net loss for the first six months of 2009 was $904,000, or $0.02 per basic and diluted share, compared with net income of $566,000, or $0.01 per basic and diluted share, for the first six months of 2008.

The gross margin percentage was 83% of net revenues for the quarter ended June 30, 2009 as compared with 86% in the second quarter of 2008. Gross profit in absolute dollars decreased by $1,684,000 to $1,845,000 for the current year second quarter as compared with $3,529,000 for the 2008 second quarter.

For the six months ended June 30, 2009, the gross margin percentage was 82% of net revenues as compared to 84% for the six months ended June 30, 2008. Gross profit in absolute dollars decreased by $1,825,000 to $4,161,000 for the six months ended June 30, 2009, as compared to $5,986,000 for the six months ended June 30, 2008. The decrease in the gross margin percentage and gross profit in dollars for the six month period is primarily attributed to a decrease in laser sales.

Research and development expenses were $346,000 in the second quarter of 2009 as compared with $252,000 in the 2008 second quarter. Year to date, R&D expenses of $634,000 were $166,000 or 35% above the prior year period of $468,000. The dollar increase for the three and six months ended June 30, 2009 was primarily attributed to the recent submissions to the Food and Drug Administration related to the Premarket Approval Application for the PEARL 8.0 handpiece and the pre-Investigational Device Exemption to initiate a feasibility trial for the PHOENIX handpiece.

Sales and marketing expenses of $1,272,000 in the quarter ended June 30, 2009 decreased $523,000, or 29%, compared with $1,795,000 for the quarter ended June 30, 2008. For the six months ended June 30, 2009, S&M expenditures totaled $2,741,000, a decrease of $581,000, or 17%, compared with $3,322,000 for the six months ended June 30, 2008. The decrease in sales and marketing expenditures for the three and six months ended June 30, 2009 was primarily due to a decrease in salary and other employee related expenses as a result of lower commissions and decreased travel expense.

General and administrative expenses for the quarter ended June 30, 2009 totaled $789,000 as compared to $900,000 during the quarter ended June 30, 2008. This represents a decrease of $111,000, or 12%. For the six months ended June 30, 2009, G&A totaled $1,645,000 as compared to $1,651,000 for the six months ended June 30, 2008. This represents a reduction of $6,000, or less than 1%.

About Cardiogenesis Corporation

Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that treat severe angina. Our market leading holmium:YAG laser system and single use fiber-optic delivery systems are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR).

For more information on Cardiogenesis and its products, please visit our website at http://www.cardiogenesis.com or the direct to patient website at http://www.heartofnewlife.com.

Safe Harbor Statement

With the exception of historical information, the statements set forth above include forward-looking statements. Any forward-looking statements in this news release are subject to numerous risks and uncertainties, many of which are outside the Company's control, that could cause actual results to differ materially. Factors that could affect the accuracy of these forward-looking statements include, but are not limited to: any inability by the Company to sustain profitable operations or obtain additional financing on favorable terms if and when needed; any failure to obtain required regulatory approvals; failure of the medical community to expand its acceptance of TMR procedures; possible adverse governmental rulings or regulations, including any FDA regulations or rulings; the Company's ability to comply with international and domestic regulatory requirements; possible adverse Medicare or other third-party reimbursement policies or adverse changes in those policies; any inability by the Company to ship product on a timely basis; the Company's ability to manage its growth; the effects of recent disruptions in global credit and equity markets and other adverse economic developments that could adversely affect the market for our products or our ability to raise needed financing; actions by our competitors; and the Company's ability to protect its intellectual property. Other factors that could cause Cardiogenesis' actual results to differ materially are discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and the Company's other filings with the Securities and Exchange Commission. The Company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.


                              CARDIOGENESIS CORPORATION
                    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                        (in thousands, except per share amounts)
                                      (unaudited)

                                         Three months ended  Six months ended
                                              June 30,           June 30,
                                           2009      2008     2009     2008
                                           ----      ----     ----     ----
    Net revenues                          $2,236   $4,119   $5,088   $7,101
    Cost of revenues                         391      590      927    1,115
                                             ---      ---      ---    -----
        Gross profit                       1,845    3,529    4,161    5,986
                                           -----    -----    -----    -----
    Operating expenses:
      Research and development               346      252      634      468
      Sales and marketing                  1,272    1,795    2,741    3,322
      General and administrative             789      900    1,645    1,651
                                             ---      ---    -----    -----
        Total operating expenses           2,407    2,947    5,020    5,441
                                           -----    -----    -----    -----
        Operating income (loss)             (562)     582     (859)     545
    Other income (expense):
    Interest expense                         (21)      (1)     (31)     (21)
    Interest income                            1       21        2       42
                                             ---      ---      ---      ---
    Total other income (expense), net        (20)      20      (29)      21
                                            ----       --     ----       --
        Income (loss) before income taxes   (582)     602     (888)     566
    Provision for income taxes                 8        -       16        -
                                             ---      ---      ---      ---
        Net income (loss)                   (590)     602     (904)     566
                                           =====      ===    =====      ===
    Net earnings (loss) per share:
      Basic                               $(0.01)   $0.01   $(0.02)   $0.01
                                          ======    =====   ======    =====
      Diluted                             $(0.01)   $0.01   $(0.02)   $0.01
                                          ======    =====   ======    =====

    Weighted average shares outstanding:
      Basic                               45,519   45,293   45,503   45,284
                                          ------   ------   ------   ------
      Diluted                             45,519   45,306   45,503   45,313
                                          ------   ------   ------   ------




                             CARDIOGENESIS CORPORATION
                       CONDENSED CONSOLIDATED BALANCE SHEETS
                                   (in thousands)

                                                       June 30,  December 31,
                                                         2009        2008
                                                      (unaudited)  (audited)
                                                      -----------   --------
                                 ASSETS

    Current assets:
      Cash and cash equivalents                           $2,709      $2,907
      Accounts receivable, net of allowance for
       doubtful accounts of $7 and $20, respectively         991       1,330
      Inventories                                          1,036       1,164
      Investments in marketable securities                     -          75
      Prepaids and other current assets                      289         395
                                                             ---         ---
        Total current assets                               5,025       5,871
    Property and equipment, net                              397         382
    Other assets, net                                         18          18
                                                             ---         ---
        Total assets                                      $5,440      $6,271
                                                          ======      ======

                  LIABILITIES AND SHAREHOLDERS' EQUITY

    Current liabilities:
      Accounts payable                                      $322        $200
      Accrued liabilities                                    936       1,103
      Deferred revenue                                       799         800
      Current portion of capital lease obligations             9           6
                                                             ---         ---
        Total current liabilities                          2,066       2,109
    Capital lease obligations, less current portion           19          13
                                                             ---         ---
        Total liabilities                                  2,085       2,122
                                                           -----       -----

    Commitments and Contingencies

    Shareholders' equity:
      Preferred stock:
        no par value; 5,000 shares authorized;
         none issued and outstanding                           -           -
      Common stock:
        no par value; 75,000 shares authorized;
         45,549 and 45,487 shares issued and
         outstanding, respectively                       174,109     173,999
      Accumulated deficit                               (170,754)   (169,850)
                                                        --------    --------
        Total shareholders' equity                         3,355       4,149
                                                           -----       -----
        Total liabilities and shareholders' equity        $5,440      $6,271
                                                          ======      ======


'/>"/>
SOURCE Cardiogenesis Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiogenesis Corporation Names Paul J. McCormick Executive Chairman
2. Cardiogenesis Reports First Quarter 2009 Results
3. Cardiogenesis Reports Fourth Quarter and Fiscal Year 2008 Results
4. Cardiogenesis Corporation to Report 2008 Fourth Quarter and Year-End Results on March 31st
5. Cardiogenesis Announces Successful Educational Symposium at Society of Thoracic Surgeons Meeting in San Francisco
6. Cardiogenesis Corporation to Report Third Quarter 2008 Results on November 13th
7. Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C.
8. Cardiogenesis Announces Preliminary Results Combining TMR + Platelet Rich Plasma (PRP)
9. Cardiogenesis Reports First Quarter 2008 Results
10. Cardiogenesis Corporation to Report 2008 First Quarter Results on May 15th
11. Cardiogenesis Corporation Announces Rescheduled Fourth Quarter and Full Year 2007 Earnings Release
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that ... you are not alone. According to the Center for Disease Control and Prevention (CDC), ... 2 diabetes and certain types of cancer, some of the leading causes of preventable ...
(Date:2/8/2016)... Francisco, CA (PRWEB) , ... February 08, 2016 , ... ... raise $792,000 to help combat pancreatic cancer. , Gary D. Radine, who recently retired ... also was the American Cancer Society’s 2015 CEO of the Year , helped ...
(Date:2/8/2016)... ... , ... Discover the Rocky Mountain region’s longest running and impressive garden and ... also get to see the most incredible gardens and home improvement experts that attend ... Colorado Convention Center - 700 14th St. Denver CO, is an exciting event that ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is ... 11th, 2016 in honor of his birthday on February 10th. During this time, ... Trivedi is known by over 250,000 people from over 40 different countries as an ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. announced today ... the tools and information to lower the costs, and increase the impact of ... providing employee healthcare benefits by as much as 22%:, + Price and ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... N.C. , Feb. 8, 2016  Avista Pharma ... Eric Setzer as Chief Financial Officer (CFO). Mr. ... twenty years of experience in various roles within growing ... Pharma, he served as the Executive Director of Finance ... in Raleigh, NC . Previously, Mr. ...
(Date:2/8/2016)... , Feb. 8, 2016 Velano Vascular, ... experience for hospitalized patients and their practitioners, announced today ... in funding. Velano will use the proceeds from this ... financing completed in January 2015, to support the development ... adult and pediatric populations. Philadelphia ...
(Date:2/8/2016)... -- Vestagen Technical Textiles, Inc., a medical technology company ... other demanding applications, today announced it has named ... Dale Pfost , PhD, who was serving as interim ... Vestagen,s Board of Directors. ® , the ... that combines fluid repellent, antimicrobial and breathability properties. VESTEX ...
Breaking Medicine Technology: